April 27, 2024

• 

[THE INVESTOR] As of Jan. 23 01:26 P.M., Samjin Pharmaceutical increased 1.87% from yesterday to 32,750 won (US$ 28.05). It fell 3.82% over the past month. Standard deviation for the one month period stood at 1.9%.

Compared with its industry competitors listed on KOSPI, the monthly earnings rate of Samjin Pharmaceutical was lower than its peer group, and its volatility for the one month was at a low level.

The monthly return-on-risk, indicating the return on investment with consideration for risk, was -2.0%. Compared with the rest of the KOSPI industry, the return-on-risk was lower than the industrial mean of 2.5%.

■ Earnings & Valuation

Earnings report for 3Q (July – Sept.) of 2016
Revenue: 611.1 T   Up 1.8% on-quarter, up 9.5% on-year
Operating income: 119.5 T   Up 10.4% on-quarter, up 17.6% on-year
Net income: 91.2 T   Up 9.6% on-quarter, up 25.1% on-year

Investor Groups (Over the past five trading days)
Institutions 21.13%, Foreigners 33.16%, Individuals 45.69%

*Other investor groups including corporations are considered as “individuals.”

By HeRo (hero@heraldcorp.com)

This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.